KEYTRUDA 25 mg/mL concentrate for solution for infusion, ENFORTUMAB VEDOTIN
MK-3475-905
Phase 3 small_molecule active
Quick answer
KEYTRUDA 25 mg/mL concentrate for solution for infusion, ENFORTUMAB VEDOTIN for Muscle Invasive Bladder Cancer is a Phase 3 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck Sharp and Dohme
- Indication
- Muscle Invasive Bladder Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active